Analyst Update: athenahealth, Inc, Adeptus Health Inc, and Sarepta Therapeutics Inc

Analysts revised their ratings and price targets on athenahealth, Inc (ATHN), Adeptus Health Inc (ADPT), and Sarepta Therapeutics Inc (SRPT)

by Alex Eppstein

Published on Jul 22, 2016 at 1:47 PM

Analysts are weighing in on healthcare stocks athenahealth, Inc (NASDAQ:ATHN) and Adeptus Health Inc (NYSE:ADPT), as well as drugmaker Sarepta Therapeutics Inc (NASDAQ:SRPT)Here's a quick roundup of today's brokerage notes on ATHN, ADPT, and SRPT.

  • ATHN is getting crushed, after the company reported a suprise second-quarter loss. The brokerage crowd is only adding to the pain, with Deutsche Bank downgrading its opinion to "hold" from "buy," and joining two other analysts in slashing its price target. "Most concerning to us is that many of Athena's key underlying operating metrics are trending in the wrong direction," Deutsche Bank said with respect to athenahealth, Inc. At last check, the shares have plunged 11.7% at $121.14, and landed on the short-sale restricted list. In fact, ATHN isn't that far from its annual low of $114.59, touched in early February. Meanwhile, traders have been betting bearishly in the last two weeks at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX). The stock's 10-day put/call volume ratio of 2.93 ranks near the top quartile of its annual range.
  • ADPT has sunk 5.3% at $46.64, on the heels of an earnings miss and negative round of analyst notes. Specifically, Jefferies, KeyBanc, and Goldman Sachs each lowered their price targets on the stock, which has now surrendered 14.5% year-to-date. Suffice it to say, Adeptus Health Inc call buyers could be feeling the heat. During the past 50 sessions at the ISE, CBOE, and PHLX, traders have bought to open 2.33 calls for each put -- a ratio that ranks in the bullishly skewed 89th percentile of its 52-week range.
  • SRPT is burning short sellers today, up 6.4% at $24.09 on a price-target hike to $26 from $20 at Needham. After all, nearly half of the stock's float is sold short, representing 6.2 times its average daily trading volume. On the charts, Sarepta Therapeutics Inc has been muscling its way higher since gapping sharply south in mid-January. That said, the shares have repeatedly been turned back in the $24-$25 area over the past several months, and now face another potential level of resistance at their overhead 320-day moving average.
Don't miss the market's next move! Sign up now for Schaeffer's Midday Market Check

A Schaeffer's exclusive

6 Sectors for Summer

Access your FREE insider report before it's too late!



NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories

The Next Big Player in U.S. MJ Boom
Most pure-play marijuana stocks in the U.S. trade on the Over-the-Counter stock exchange.
Wall Street Roars Higher Amid Civil Unrest
Investors weighed a mixed bag of jobs data
AstraZeneca Stock Flat Despite COVID-19 Vaccine News
AstraZeneca saw a rise in capacity for its COVID-19 vaccine candidate
The Next Big Player in U.S. MJ Boom
Most pure-play marijuana stocks in the U.S. trade on the Over-the-Counter stock exchange.